About Anup Madan, Ph.D.

Anup Madan, Ph.D. is a Principal Scientist and Genomics/Associate Director for the Sequencing Group at Covance. He is responsible for developing next generation sequencing platforms and providing sequence-based assays as core services of Covance Genomics Laboratory, as well as developing novel MDx assays to support various clinical trials. Anup played a key role in the sequencing of the human genome and made significant contributions to understand the etiology of brain tumors. He has published extensively in reputable journals such as Science, Nature and Cancer Research. Anup has a Ph.D. in Biochemical Genetics from Tata Institute of Fundamental Research in Mumbai, India.

Using Next-Generation Sequencing to Detect Epigenetic Alterations – The Impact on Clinical Oncology

Using Next Generation Sequencing to Detect Epigenetic Alterations - The Impact on Clinical Oncology

How can identical twins, with the same genetic makeup, experience different diseases? Scientists believe this is due to epigenetic marks or chemical tags that play a role in controlling the activities of genes. The study of the epigenetic landscape has already generated recent breakthroughs in the detection, treatment and prognosis of many diseases, including cancer.

These breakthroughs are due in part to large-scale mapping efforts of cancer genomes coupled with the rapidly dropping costs of high-throughput next-generation sequencing technologies. Identification of mutations and epigenetic analysis are the next frontier for finding reliable biomarkers and developing targeted therapies.

Next-generation sequencing platforms are particularly powerful for mutational and epigenetic studies due to their ability to quickly analyze the entire genome through multiple methods of sequencing, such as DNA, RNA, miRNA, whole genome, exome, targeted, ChIP-Seq, methylome and epigenome. As a result, researchers obtain comprehensive, clinically relevant data sets.

With these resulting data, computational biologists can mine both open source data sets along with data sets from clinical trials to narrow down options for prospective biomarkers. Continue reading